Baba Hideo A, Stypmann Jörg, Grabellus Florian, Kirchhof Paulus, Sokoll Andrea, Schäfers Michael, Takeda Atsushi, Wilhelm Markus J, Scheld Hans H, Takeda Nobuakira, Breithardt Günter, Levkau Bodo
Institute of Pathology, University of Essen, Essen, Germany.
Cardiovasc Res. 2003 Aug 1;59(2):390-9. doi: 10.1016/s0008-6363(03)00393-6.
Left ventricular assist devices (LVAD) are used to 'bridge' patients with end-stage heart failure to transplantation. After long-term LVAD support, ventricular function may partially recover, a process called 'reverse remodeling'. As several kinase-mediated signal transduction pathways have been implicated in the development of cardiac hypertrophy and failure, we examined the activities of the Erks, MEKs, Akt, GSK-3 beta, p70S6K, JNKs and p38 under LVAD support as well as during single myocyte strain and whole heart stretch.
Western blotting and immunohistochemistry were performed using phospho-specific antibodies in matched samples from ten patients with end-stage heart failure before and after LVAD. Cyclic strain was performed in rat neonatal cardiac myocytes, and tensile stretch applied to Langendorff-perfused mouse hearts via a left ventricular balloon.
The activity of Erks and Akt in failing hearts dramatically decreased after LVAD support, while that of GSK-3 beta increased. There was an endo/epicardial gradient for Erk activity which persisted after LVAD despite the reduction of total Erk activity. TUNEL-positivity and myocyte size decreased after LVAD, but independently of changes in kinase activity. In cardiomyocytes and Langendorff-perfused mouse hearts both strain/stretch and its relief regulated the activities of Erks, Akt, and GSK-3 beta.
Erks and Akt/GSK-3 beta are highly responsive to myocyte stretch in vitro and in vivo, and may be sensitive molecular parameters of 'reverse remodeling' under LVAD support.
左心室辅助装置(LVAD)用于将终末期心力衰竭患者“过渡”到心脏移植。长期LVAD支持后,心室功能可能部分恢复,这一过程称为“逆向重构”。由于几种激酶介导的信号转导途径与心肌肥大和心力衰竭的发生有关,我们检测了LVAD支持下以及单个心肌细胞拉伸和全心拉伸过程中细胞外信号调节激酶(Erks)、丝裂原活化蛋白激酶激酶(MEKs)、蛋白激酶B(Akt)、糖原合成酶激酶-3β(GSK-3β)、核糖体蛋白S6激酶(p70S6K)、应激活化蛋白激酶(JNKs)和p38的活性。
使用磷酸化特异性抗体对10例终末期心力衰竭患者在LVAD植入前后的匹配样本进行蛋白质印迹法和免疫组织化学检测。对大鼠新生心肌细胞进行周期性拉伸,并通过左心室球囊对Langendorff灌注的小鼠心脏施加拉伸。
LVAD支持后,衰竭心脏中Erks和Akt的活性显著降低,而GSK-3β的活性增加。尽管总Erk活性降低,但LVAD后仍存在心内膜/心外膜的Erk活性梯度。LVAD后TUNEL阳性率和心肌细胞大小降低,但与激酶活性变化无关。在心肌细胞和Langendorff灌注的小鼠心脏中,拉伸及其解除均调节Erks、Akt和GSK-3β的活性。
Erks和Akt/GSK-3β在体外和体内对心肌细胞拉伸高度敏感,可能是LVAD支持下“逆向重构”的敏感分子参数。